Surgery for Malignant Pleural Mesothelioma Improves Quality of Life

Patients who underwent an operation called pleurectomy and decortication (PD) generally reported their quality of life improved after surgery.

Malignant pleural mesothelioma is caused by environmental factors such as exposure to asbestos as well as a genetic predisposition to the cancer. It develops in the pleura, the thin layer of tissue surrounding the lungs. As the tumor grows, it restricts the lungs, typically causing shortness of breath, fatigue, weight loss and/or chest discomfort and pain.

Although surgery can prolong the lives of patients with this aggressive type of cancer, many patients avoid the operation for fear it will degrade their quality of life.

New Protein Test to Detect Pulmonary Cancer
A novel protein test to detect early-stage, asbestos-related pulmonary cancer have been developed by researchers at NYU Langone Medical Center.

‘Malignant pleural mesothelioma patients who underwent an operation called pleurectomy and decortication (PD) generally reported their quality of life improved after surgery.’

But a study led by a Loyola Medicine thoracic surgeon has found just the opposite. Patients who underwent an operation called pleurectomy and decortication (PD) generally reported their quality of life improved after surgery.

Wickii Vigneswaran, presented the study during the 2016 annual meeting of the American Society of Clinical Oncology. Dr. Vigneswaran is division director of thoracic surgery and a professor in the department of thoracic and cardiovascular surgery of Loyola University Chicago Stritch School of Medicine.

In PD surgery, the pleura is removed. While the procedure cannot cure mesothelioma, it can help control the buildup of fluid, improve breathing and lessen cancer pain.

Biomarkers can Distinguish Mesothelioma from Non-Cancerous Tissue
Researchers have identified 4 biomarkers that may resolve the difficult differential diagnosis between malignant pleural mesothelioma (MPM) and non-cancerous pleural tissue with reactive mesothelial proliferations (RMPs).

Dr. Vigneswaran and colleagues administered a cancer quality-of-life survey known as the EORTC QLQ-C30 to 114 mesothelioma patients who underwent PD surgery. The median age was 70, with a range of 50 to 88. Prior to surgery, 31% of the patients had a performance status score of zero (fully functional); 65% had a performance status score of one (able to do light house work or office work); and 4% had a performance status of two (ambulatory and capable of self-care, but unable to work). Following surgery, all patients were surveyed at one month, four-five months, seven-eight months and 10-11 months.

The quality of life survey measured overall functioning (physical, emotional, cognitive, etc.); general symptoms (fatigue, nausea/vomiting and pain); individual items (shortness of breath, diarrhea, insomnia, constipation and financial difficulties) and overall health.

New Findings on Treatment Options for Mesothelioma
Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival.

Improved quality of life was observed in the first month after surgery and was maintained at late follow-up in all patients. Quality of life was not adversely affected by surgery at any time in patients who, prior to surgery, had performance status of one or two; a tumor volume greater than 600 ml. or a type of tumor cell called non-epithelioid.

"The net benefit of pleurectomy and decortication justifies the procedure in the majority of patients with malignant pleural mesothelioma," Dr. Vigneswaran concluded.

Mesothelioma Drug Slows Disease Progression in Patients With an Inactive NF2 Gene: Study
Some success shown in preventing the spread of the deadly disease in patients lacking an active tumour suppressor gene called NF2 by preliminary findings.

The study is titled 'Quality of Life in Patients Undergoing Pleurectomy and Decortication for Malignant Pleural Mesothelioma'. The surgeries were performed by Dr. Vigneswaran at University of Chicago Medicine, where he practiced before recently joining Loyola.

Source-Newswise